Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with Staphylococcus aureus

BMC Microbiology

Volumn 9, Issue , 2009, Pages

  Zimecki, Michał ^a   Artym, Jolanta ^a   Kociȩba, Maja ^a   Weber Da̧browska, Beata ^a   Borysowski, Jan ^b   Gárski, Andrzej ^a,b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLUTININ; CYCLOPHOSPHAMIDE; INTERLEUKIN 6; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; BACTERIUM ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIOPHAGE; BACTERIUM COLONY; BONE MARROW; CELL LINEAGE; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; IMMUNE DEFICIENCY; IMMUNOPROPHYLAXIS; LYMPHOCYTE; MALE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PROMYELOCYTE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME; ANIMAL; BLOOD; CBA MOUSE; GRANULOCYTE PRECURSOR; IMMUNOLOGY; MICROBIOLOGY; NEUTROPHIL; STAPHYLOCOCCUS PHAGE; VIROLOGY;

BACTERIA (MICROORGANISMS); MUS; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTIBODIES, BACTERIAL; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; GRANULOCYTE PRECURSOR CELLS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; MALE; MICE; MICE, INBRED CBA; NEUTROPHILS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS PHAGES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349145427     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-9-169     Document Type: Article

References (45)

1. Bacteriophage therapy for the treatment of infections. A Gárski R Midzybrodzki J Borysowski B Weber-Dbrowska M obocka W Fortuna S Letkiewicz M Zimecki G Filby, Curr Opin Investig Drugs 2009 10 766 774 19649921
2. Effect on the human normal microflora of oral antibiotics for treatment of urinary tract infections. C Edlund CE Nord, J Antimicrob Chemother 2000 46 41 48 10.1093/jac/46.suppl-1.41
3. Effects of penicillin on the humoral and cellular immune response following group A streptococcal. RA Zimmerman PH Klesius DH Krushak JH Mathews, Can J Comp Med 1975 39 227 230 804981
4. Effective phage therapy is associated with normalization of cytokines production by blood cell cultures. B Weber-Dbrowska M Zimecki M Mulczyk, Arch Immunol Ther Exp (Warsz) 2000 48 31 38 10722229
5. Effect of phage therapy on the turnover and function of peripheral neutrophils. B Weber-Dbrowska M Zimecki M Mulczyk A Gárski, FEMS Immunol Med Microb 2002 34 135 138 10.1111/j.1574-695X.2002.tb00614.x
6. Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes. R Midzybrodzki K witaa-Jele W Fortuna B Weber-Dbrowska A Przerwa M usiak-Szelachowska K Dbrowska A Kurzepa J Boratyski D Syper G Poniak C ugowski A Gárski, Virus Res 2008 131 233 242 10.1016/j.virusres.2007.09.013 17996972
7. Effects of bacteriophages on free radical production and phagocytic fuctions. A Przerwa M Zimecki K witaa-Jele K Dbrowska E Krawczyk M uczak B Weber-Dbrowska D Syper R Midzybrodzki A Gárski, Med Microbiol Immunol 2005 195 143 150 10.1007/s00430-006-0011-4
8. Anticancer activity of bacteriophage T4 and its mutant HAP1 in mouse experimental tumour models. K Dbrowska A Opolski J Wietrzyk K witaa-Jele J Godlewska J Boratyski D Syper B Weber-Dbrowska A Gárski, Anticancer Res 2004 24 3991 3995 15736444
9. Population and evolutionary dynamics of phage therapy. BR Levin JJ Bull, Nat Rev Microbiol 2004 2 166 173 10.1038/nrmicro822 15040264
10. Immunogenic effect of bacteriophages in patients subjected to phage therapy. A Kucharewicz-Krukowska S lopek, Arch Immunol Ther Exp (Warsz) 1987 35 553 561 3455646
11. Antibody producing capacity to the bacteriophage phi X174 in yersinia arthritis. R Bucknall M Leirisalo-repo 0 Laitinen JV Jones, Ann Rheum Dis 1987 46 883 888 10.1136/ard.46.12.883 2962540 (Pubitemid 18025560)
12. Viruses of prokaryotes. HW Ackermann MS Dubow, General properties of bacteriophages CRC Press Boca Raton, FL 1987 1 49 76
13. Morphological varieties and host rouge of vibrio parahaemolyticus bacteriophages isolated from sea water. T Koga S Toyoshima T Kawata, Appl Environ Microbiol 1982 44 466 470 7125657
14. Bacteriophage therapy. A Sulakvelidze JG Morris, Antimicrob Agents Chemother 2001 45 649 659 10.1128/AAC.45.3.649-659.2001 11181338
15. In vivo lysogenic conversion of Tox (-) Streptococcus pyogenes to Tox (+) with lysogenic Streptococcus or free phage. TB Broudy VA Fischetti, Infect Immun 2003 71 3782 3786 10.1128/IAI.71.7.3782-3786.2003 12819060
16. Is phage therapy acceptable in the immunocompromised host? J Borysowski A Gárski, Int J Infect Dis 2008 12 466 471 10.1016/j.ijid.2008.01.006 18400541
17. Bacteriophage therapy for infections in cancer patients. B Weber-Dbrowska M Mulczyk A Gárski, Clin Appl Immunol Rev 2001 1 131 134 10.1016/S1529-1049(01)00015-0
18. Bacteriophages in Medicine. A Gárski J Borysowski R Midzybrodzki B Weber-Dbrowska, Bacteriophage: Genetics and Molecular Biology Norfolk: Caister Academic Press, Mc Grath S, van Sinderen D, 2007 125 158
19. Bacteriophages and transplantation tolerance. A Gárski M Kniotek A Perkowska-Ptasiska A Mráz A Przerwa W Gorczyca K Dbrowska B Weber-Dbrowska M Nowaczyk, Transplant Proc 2006 38 331 333 10.1016/j. transproceed.2005.12.073 16504739
20. Phagocytic cell function in response to immunosuppressive therapy. DB Drath BD Kahan, Arch Surg 1984 119 156 160 6320765
21. Nadir neutrophil counts in patients treated for breast cancer with doxorubicin and cyclophosphamide. NA Othieno-Abinya LO Nyabola AO Nyong'o R Baraza, East Afr Med J 2001 78 370 372 11957262
22. The effect of intravenous cyclophosphamide pulse on peripheral blood lymphocytes in lupus erythematosus patients. JK Lacki SH Mackiewicz P Leszczyski W Muller, Rheumatol Int 1997 17 55 60 10.1007/PL00006852 9266621
23. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. MJ Leandro JC Edwards G Cambridge, Ann Theum Dis 2002 61 883 888 10.1136/ard.61.10.883
24. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. HL Weiner JA Cohen, Mult Scler 2002 8 142 154 10.1191/1352458502ms790oa 11990872
25. Long-term remission in an elderly patients with mantle cell leukemia treated with low-dose cyclophosphamide. N Asou H Suzushima S Hishimura T Okubo H Yamasaki M Osato K Hoshino K Takatsuki H Mitsuya, Am J Haematol 2000 63 35 37 10.1002/(SICI)1096-8652(200001)63:1<35::AID-AJH83.0.CO;2-L
26. Immunomodulatory effects of moxifloxacin in comparison to ciproflaxin and G-CSF in a murine model of cyclophosphamide-induced leucopenia. I Shalit Y Kletter D Halperin D Waldman E Vasserman A Nagler I Fabian, Eur J Haematol 2001 66 287 296 10.1034/j.1600-0609.2001.066005287.x 11422407
27. Orally administered lactoferrin restores humoral immune response in immunocompromised mice. J Artym M Zimecki M Paprocka ML Kruzel, Immunol Lett 2003 89 9 15 10.1016/S0165-2478(03)00102-0 12946859
28. Reconstitution of the cellular immune response by lactoferrin in cyclophosphamide-treated mice is correlated with renewal of T cell compartment. J Artym M Zimecki ML Kruzel, Immunobiology 2003 207 197 205 10.1078/0171-2985- 00233 12777061
29. Normalization of peripheral blood cell composition in cyclophosphamide treated mice by lactoferrin. J Artym M Zimecki ML Kruzel, Med Sci Monit 2004 10 R84 89 14976460
30. Bacteriophages provide regulatory signals in mitogen-induced murine splenocyte proliferation. M Zimecki B Weber-Dbrowska M usiak-Szelachowska M Mulczyk J Boratyski G Poniak D Syper A Gárski, Cell Mol Biol Lett 2003 8 699 711 12949610
31. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. T Espevik J Nissen-Meyer, J Immunol Methods 1986 95 99 105 10.1016/0022-1759(86)90322-4 3782828
32. Purification and NH2-terminal amino acid sequence of a T-cell-derived lumphokine with growth factor activity for B-cell hybridomas. J Van Snick S Cayphas A Vink C Uyttenhove PG Coulie MR Rubira RJ Simpson, Proc Natl Acad Sci USA 1986 83 9679 9683 10.1073/pnas.83.24.9679 2948184
33. Increased bone marrow production of granulocytes and mononuclear phagocytes induced by mycobacterial adjuvants: improved recovery of leucopoiesis in mice after cyclophosphamide treatment. WC Buhles Jr M Shifrine, Infect Immun 1978 20 58 65 352938
34. The effect of different infectious agents on the intensification of hematopoiesis during immunosuppression. MR Karpova IF Zveveva V Novitski, Zh Mikrobiol Epidemiol Immunobiol 1999 6 63 67 10876854
35. Mouse bone marrow contains large numbers of functionally competent neutrophils. R Boxio C Bossenmeyer-Pourie N Steinckwich C Dournon O Nsse, J Leukoc Biol 2004 75 604 611 10.1189/jlb.0703340 14694182
36. Bacteria in the blood-stream are trapped in the liver and killed by immigrating neutrophils. SH Gregory AJ Sagnimeni EJ Wing, J Immunol 1996 157 2514 2520 8805652
37. Complementary adhesion molecules promote neutrophil-Kupffer cell interaction and elimination of bacteria taken up by the liver. SH Gregory LP Cousens N van Rooijen EA Dopp TM Carlos EJ Wing, J Immunol 2002 168 308 315 11751975
38. Selective mitomycin C and cyclophosphamide induction of apoptosis in differentiating B lymphocytes compared to T lymphocytes in vivo. RA Hemendinger SE Bloom, Immunopharmacology 1996 35 71 82 10.1016/0162-3109(96)00124-5 8913797
39. Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents. J Li HK Law YL Lau GC Chan, Br J Haematol 2004 127 326 334 10.1111/j.1365-2141.2004.05200.x 15491295
40. RM-11, an isoxazole derivative, accelerates restoration of the immune function in mice treated with cyclophosphamide. M Zimecki J Artym S Ryng B Obmiska-Mrukowicz, Pharmacol Rep 2008 60 183 189 18443379
41. Neutrophils are essential for rapid clearance of Enterococcus faecium in mice. M Leendertse RJ Willems IA Giebelen JJ Roelofs MJ Bonten T van der Poll, Infect Immun 2009 77 485 491 10.1128/IAI.00863-08 19001080
42. Intracellular survival of Staphylococcus aureus: correlating production of catalase and superoxidase dismutase with levels of inflammatory cytokines. D Das SS Saha B Bishayi, Inflam Res 2008 57 340 349 10.1007/s00011-007-7206-z
43. Antibiotic-induced bacterial killing stimulates tumor necrosis factor-alpha release in whole blood. M Arditi W Kabat R Yogev, J Infect Dis 1993 167 240 244 8418175
44. Differential modulation of the induction of inflammatory mediators by antibiotics in mouse macrophages in response to viable Gram-positive and Gram-negative bacteria. W Cui MG Lei R Silverstein DC Morrison, J Endotoxin Res 2003 9 225 236 10.1179/096805103225001422 12935353
45. Anti-tumor necrosis factor antibody reduces mortality in the presence of antibiotic-induced tumor necrosis factor release. RG Sawyer RB Adamus AK May LK Rosenlof TL Pruett, Arch Surg 1993 128 73 77 8418784